CATT

CATL's German plant kicks off cell production

Retrieved on: 
Wednesday, December 21, 2022

The first batch of lithium-ion battery cells rolled off the newly installed production line under series condition in CATT's G2 building.

Key Points: 
  • The first batch of lithium-ion battery cells rolled off the newly installed production line under series condition in CATT's G2 building.
  • The locally produced cells passed all tests that are required of CATL's products globally, which proves CATL is capable of starting cell production and supplying cells to its European customers from its local plant.
  • CATT received the permit for battery cell production from the state of Thuringia this April, which allows an initial capacity of 8 GWh per year.
  • The plant has already started module production in its G1 building in Q3 2021.

CATL's German plant kicks off cell production

Retrieved on: 
Wednesday, December 21, 2022

The first batch of lithium-ion battery cells rolled off the newly installed production line under series condition in CATT's G2 building.

Key Points: 
  • The first batch of lithium-ion battery cells rolled off the newly installed production line under series condition in CATT's G2 building.
  • The locally produced cells passed all tests that are required of CATL's products globally, which proves CATL is capable of starting cell production and supplying cells to its European customers from its local plant.
  • CATT received the permit for battery cell production from the state of Thuringia this April, which allows an initial capacity of 8 GWh per year.
  • The plant has already started module production in its G1 building in Q3 2021.

Verana Health to Present Findings of Studies Using American Academy of Ophthalmology IRIS® Registry Data to Advance Insights into Real World Outcomes in Treating AMD

Retrieved on: 
Wednesday, November 2, 2022

SAN FRANCISCO, Nov. 2, 2022 /PRNewswire/ -- During The Retina Society's 55th Annual Scientific Meeting Nov. 2 to 5, Verana Health®—a digital health company elevating quality in real-world data—will present findings on two separate studies that utilize curated real-world data (RWD) from the American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight).

Key Points: 
  • treatment arms of the CATT trial using de-identified IRIS Registry data from a real-world population to compare treatment outcomes at one year to the monthly treatment arms of the CATT using patient-level clinical trial data.
  • Established in 2014, the IRIS Registry is one of the largest specialty society clinical data registries in all of medicine.
  • Using its clinician-informed and artificial intelligence-enhanced VeraQpopulation health data engine, Verana Health transforms structured and unstructured healthcare data into curated, disease-specific data modules, Qdata.
  • Verana Health's quality data and insights help drive progress in medicine to enhance the quality of care and quality of life for patients.

Ophthalmic Images Now Available through the Academy IRIS® Registry, Curated at Scale by Verana Health's VeraQ Engine

Retrieved on: 
Thursday, September 29, 2022

SAN FRANCISCO , Sept. 29, 2022 /PRNewswire/ -- Verana Health® announced today the introduction of ophthalmic images into its VeraQ™ population health data engine. The ~3.5 million images—spanning optical coherence tomography (OCT), fundus autofluorescence, color fundus photography, and more—are being incorporated into the Academy IRIS® Registry. This data is managed by Verana Health via VeraQ, where it is linked with de-identified electronic health record (EHR) data and curated with clinician oversight and artificial intelligence (AI), such as machine learning (ML), to produce quality data variables and Ophthalmology Qdata™ modules. These image-derived variables and Qdata modules—being introduced to the ophthalmic community at the Academy's Annual Meeting (AAO 2022)—will be selectively available in the future to academic research institutions participating in the IRIS Registry Analytic Center Consortium and life sciences organizations, respectively.

Key Points: 
  • American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) extends data footprint by making available data from more than 3.5 million images of eyes.
  • SAN FRANCISCO, Sept. 29, 2022 /PRNewswire/ -- Verana Health announced today the introduction of ophthalmic images into its VeraQ population health data engine.
  • The ~3.5 million imagesspanning optical coherence tomography (OCT), fundus autofluorescence, color fundus photography, and moreare being incorporated into the Academy IRIS Registry.
  • Using its clinician-informed and artificial intelligence-enhanced VeraQpopulation health data engine, Verana Health transforms structured and unstructured healthcare data into curated, quality data modules, Qdata.

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Retrieved on: 
Tuesday, August 30, 2022

In anticipation of potential FDA marketing approval in 2023, Outlook Therapeutics has continued its commercial launch planning.

Key Points: 
  • In anticipation of potential FDA marketing approval in 2023, Outlook Therapeutics has continued its commercial launch planning.
  • These activities include establishing best-in-class partnerships with FUJIFILM Diosynth Biotechnologies for drug substance, and with drug product manufacturer Ajinomoto Bio-pharma Services for finished drug product.
  • NORSE ONE was a clinical experience trial involving 61 wet AMD participants at nine trial sites in Australia.
  • Outlook Therapeutics has submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010 to treat wet AMD.

CATL's German plant receives approval for battery cell production

Retrieved on: 
Wednesday, April 6, 2022

ARNSTADT, Germany, April 6, 2022 /PRNewswire/ -- On April 4, Contemporary Amperex Technology Thuringia GmbH (CATT), CATL's first plant outside of China, received the 2nd partial approval for the commissioning of a new plant for battery cell production from the state of Thuringia, Germany, marking a significant milestone for CATL's global footprint expansion despite the pandemic.

Key Points: 
  • ARNSTADT, Germany, April 6, 2022 /PRNewswire/ -- On April 4, Contemporary Amperex Technology Thuringia GmbH (CATT), CATL's first plant outside of China, received the 2nd partial approval for the commissioning of a new plant for battery cell production from the state of Thuringia, Germany, marking a significant milestone for CATL's global footprint expansion despite the pandemic.
  • The approval on Monday was issued to permit cell production of G2.
  • With clean rooms, technical cleanliness and constant humidity, the plant is almost as complex as a chip factory.
  • CATL broke ground on its German plant in 2019, and it is scheduled to start cell production by the end of 2022, when a total of 1,500 jobs will be created in Germany.

CATL's German plant receives approval for battery cell production

Retrieved on: 
Wednesday, April 6, 2022

ARNSTADT, Germany, April 5, 2022 /PRNewswire/ -- On April 4, Contemporary Amperex Technology Thuringia GmbH (CATT), CATL's first plant outside of China, received the 2nd partial approval for the commissioning of a new plant for battery cell production from the state of Thuringia, Germany, marking a significant milestone for CATL's global footprint expansion despite the pandemic.

Key Points: 
  • ARNSTADT, Germany, April 5, 2022 /PRNewswire/ -- On April 4, Contemporary Amperex Technology Thuringia GmbH (CATT), CATL's first plant outside of China, received the 2nd partial approval for the commissioning of a new plant for battery cell production from the state of Thuringia, Germany, marking a significant milestone for CATL's global footprint expansion despite the pandemic.
  • The approval on Monday was issued to permit cell production of G2.
  • With clean rooms, technical cleanliness and constant humidity, the plant is almost as complex as a chip factory.
  • CATL broke ground on its German plant in 2019, and it is scheduled to start cell production by the end of 2022, when a total of 1,500 jobs will be created in Germany.

Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Retrieved on: 
Thursday, March 31, 2022

If approved, LYTENAVA (bevacizumab-vikg) could replace the current practice of using unapproved repackaged IV bevacizumab sourced from compounding pharmacies for the treatment of wet AMD.

Key Points: 
  • If approved, LYTENAVA (bevacizumab-vikg) could replace the current practice of using unapproved repackaged IV bevacizumab sourced from compounding pharmacies for the treatment of wet AMD.
  • NORSE ONE was a clinical experience trial involving 61 wet AMD participants at nine trial sites in Australia.
  • If approved, ONS-5010 can replace the need to use unapproved repackaged IV bevacizumab from compounding pharmacies for the treatment of wet AMD.
  • Outlook Therapeutics has submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010 to treat wet AMD.

Agencies in 12 States Now Using INRIX Signal Analytics to Find and Reduce Excessive Delays and Emissions

Retrieved on: 
Friday, January 21, 2022

The City of Austin is adjusting signal timing to reduce delay as traffic volumes and patterns shift throughout the COVID-19 pandemic.

Key Points: 
  • The City of Austin is adjusting signal timing to reduce delay as traffic volumes and patterns shift throughout the COVID-19 pandemic.
  • Others leveraging Signal Analytics include agencies in California, Maryland, Massachusetts, Nevada, New Jersey, New York, North Carolina, Ohio, Oregon, Texas, Rhode Island, and Washington.
  • Signal Analytics is a cost-effective tool to reduce emissions immediately and ensure continued emission reductions by eliminating needless vehicle idling.
  • To learn more about how INRIX Signal Analytics can find and reduce excessive delays and emissions, please visit https://inrix.com/products/signal-analytics/ .

Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference

Retrieved on: 
Saturday, November 13, 2021

ISELIN, N.J., Nov. 13, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010, an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD) and other retinal indications, at the Retinal Subspecialty Day, AAO 2021 Annual Conference.

Key Points: 
  • It will be great for patients and their doctors to have more FDA-approved anti-VEGF options that are prepared specifically for intraocular use.
  • The NORSE TWO Phase 3 pivotal trial enrolled a total of228 wetAMD patients at 39 clinical trial sites inthe United States.
  • NORSE TWO data showed a strong safety profile, results consistent with previously reported safety data for ONS-5010, and similar to safety levels reported in prior research for bevacizumab used off-label in ophthalmology.
  • Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway.